RESUMO
OBJECTIVE@#To investigate the effect of local administration of deferoxamine mesylate (DFO) on vascularization and osteogenesis and its ability to maintain the activity of hypoxia inducible factor-1α (HIF-1α), by constantly observing early changes of vessel-like structures and bone tissues during bone defects healing.@*METHODS@#Skull critical bone defect models were constructed on a total of thirty male SD rats (6-8 weeks old). The rats were randomly divided into experimental group (DFO group) or control group (normal saline group). 300 μL 200 μmol/L DFO solution or normal saline was locally injected on the 4th day after the defect was made. On the 5th, 7th, 10th, 14th, and 28th days after surgery, three rats in each group were sacrificed respectively. HE staining and Masson staining were performed to observe new bone formation and mineralization. HIF-1α immunohistochemistry staining was performed to examine relative expression of protein. Qualitative analysis and comparation were performed by t-tests on relative expression of HIF-1α, numbers of blood vessels and percentages of mineralization tissues of new bone areas.@*RESULTS@#On the 5th, 7th, 10th, 14th and 28th days after surgery, the average numbers of blood vessels were 30.40±12.15, 62.00±17.87, 73.43±15.63, 40.00±7.84, 48.71±11.64 in the DFO group, and 18.75±6.63, 19.13±2.80, 51.35±16.21, 27.18±7.32, 30.88±13.43 in the control group. The number of blood vessels in the DFO group was significantly higher than that of the control group at each time point (P < 0.05). The mass of new bone in the DFO group was higher than that in the control group on the 14th and 28th days after surgery. The percentage of mineralization tissues of new bone area on the 14th and 28th days after injection were (27.73±5.93)% and (46.53±3.66)% in the DFO group, and (11.99±2.02)% and (31.98±4.22)% in the control group. The percentage of mineralization tissues in the DFO group was significantly higher than that of the control group at each time point (P < 0.001). The relative expression of HIF-1α in the DFO group compared with the control group was 2.86±0.48, 1.32±0.26, 1.32±0.32, 1.28±0.38 and 1.05±0.34 on the 5th, 7th, 10th, 14th and 28th days, with significant expression difference on the 5th day (P < 0.01).@*CONCLUSION@#Use of DFO in bone defects promotes vascularization and osteogenesis in the defect area, and maintains the protein activity of HIF-1α temporarily.
Assuntos
Animais , Masculino , Ratos , Regeneração Óssea , Desferroxamina/uso terapêutico , Ratos Sprague-Dawley , CrânioRESUMO
ABSTRACT A 10-year-old Malay girl with underlying HbE/beta-thalassemia, on regular blood transfusion and deferoxamine iron chelation therapy, presented with two-month history of bilateral blurring of vision. On examination, her vision was 6/36 both eyes. Other optic nerve functions were normal. Anterior segment examination of both eyes was unremarkable. Fundus examination of both eyes revealed dull foveal reflex. Optical coherence tomography of both maculae showed increased central subfield thickness. Fundus fluorescence angiography showed patchy hypofluorescence over macular region for both eyes and late staining, indicating retinal pigment epithelium anomalies. A diagnosis of iron-chelation-therapy-related bilateral maculopathy was made. Patient was co-managed with pediatric hematology team to adjust the dose of deferoxamine, and was given three monthly appointments to monitor the progression of maculopathy at the ophthalmology clinic. However patient defaulted ophthalmology follow-up after the first visit.
RESUMO Uma menina malaia de 10 anos de idade com doença de base- B/beta-talassemia, em transfusão de sangue regular e terapia quelante de ferro deferoxamina, apresentou história de dois meses de visão turva bilateral. Ao exame, sua visão era de 6/36 em ambos os olhos. Outras funções do nervo óptico estavam normais. O exame do segmento anterior de ambos os olhos foi normal. Exame do fundo de ambos os olhos revelou reflexo foveal opaco. A tomografia de coerência óptica de ambas as máculas mostrou aumento da espessura do subcampo central. A angiografia de fluorescência do fundo mostrou hipofluorescência irregular sobre a região macular de ambos os olhos e coloração tardia, indicando anomalias de epitélio pigmentar da retina. Um diagnóstico de maculopatia bilateral relacionada à terapia quelante de ferro foi feito. A paciente foi avaliada em conjunto com a equipe de hematologia pediátrica para ajustar a dose de deferoxamina, e foram oferecidas três consultas mensais na clínica oftalmológica, para monitorar a progressão da maculopatia. No entanto, ela não compareceu para acompanhamento oftalmológico após a primeira visita.
Assuntos
Humanos , Feminino , Criança , Sideróforos/efeitos adversos , Talassemia beta/tratamento farmacológico , Desferroxamina/efeitos adversos , Reação Transfusional , Degeneração Macular/complicações , Transfusão de Sangue , Sideróforos/uso terapêutico , Talassemia beta/diagnóstico , Desferroxamina/uso terapêuticoRESUMO
RESUMO Objetivo: Avaliar a efetividade da estratificação para identificar e escolher alvos para terapia antioxidante em um modelo de sepse letal em animais e pacientes que desenvolveram hipotensão prolongada. Métodos: Submeteu-se um grupo de ratos à sepse induzida por ligadura e punção do ceco. Os animais foram divididos em dois grupos: os com níveis plasmáticos altos e os com níveis plasmáticos baixos de interleucina-6. Após a estratificação, administrou-se aos animais N-acetilcisteína mais desferroxamina ou soro fisiológico a partir de 3 e 12 horas após a cirurgia. Em pacientes hipotensos, N-acetilcisteína mais desferroxamina ou placebo foram administrados dentro de 12 horas após o cumprimento dos critérios para inclusão. Resultados: O uso de N-acetilcisteína mais desferroxamina aumentou a sobrevivência no modelo com ligadura mais punção do ceco quando a administração ocorreu 3 e 12 horas após indução da sepse. Ao utilizar os níveis de interleucina-6 para separar os animais que receberam antioxidantes, o efeito protetor só foi observado nos animais que tinham níveis elevados de interleucina-6. O efeito antioxidante de N-acetilcisteína mais desferroxamina foi similar nos dois grupos, porém observou-se diminuição significante dos níveis plasmáticos de interleucina-6 no grupo que apresentava elevado nível de interleucina-6. Em comparação com pacientes tratados com antioxidantes no subgrupo que tinha baixos níveis plasmáticos de interleucina-6, aqueles que tinham níveis elevados de interleucina-6 tiveram menor incidência de lesão renal aguda, porém não foram diferentes em termos de severidade da lesão renal aguda ou da mortalidade na unidade de terapia intensiva. Conclusão: Direcionar a terapia antioxidante para um elevado fenótipo inflamatório selecionaria uma população responsiva.
ABSTRACT Objective: To examine the effectiveness of stratification to identify and target antioxidant therapy for animal models of lethal sepsis and in patients who develop sustained hypotension. Methods: Rats were subjected to sepsis induced by cecal ligation and puncture. Animals were divided into two groups: those with high and low plasma levels of interleukin-6. Following stratification, N-acetylcysteine plus deferoxamine or saline was administered to animals starting 3 and 12 hours after surgery. N-Acetylcysteine plus deferoxamine or placebo was administered within 12 hours of meeting the inclusion criteria in hypotensive patients. Results: N-Acetylcysteine plus deferoxamine increased survival in the cecal ligation and puncture model when administered 3 and 12 hours after sepsis induction. When dividing animals that received antioxidants using plasma interleukin-6 levels, the protective effect was observed only in those animals with high IL-6 levels. The antioxidant effect of N-acetylcysteine + deferoxamine was similar in the two groups, but a significant decrease in plasma interleukin-6 levels was observed in the high-interleukin-6-level group. Compared with patients treated with antioxidants in the low-interleukin-6 subgroup, those in the high-interleukin-6 subgroup had a lower incidence of acute kidney injury but were not different in terms of acute kidney injury severity or intensive care unit mortality. Conclusion: Targeting antioxidant therapy to a high inflammatory phenotype would select a responsive population.
Assuntos
Humanos , Animais , Masculino , Adulto , Pessoa de Meia-Idade , Idoso , Ratos , Acetilcisteína/uso terapêutico , Sepse/tratamento farmacológico , Desferroxamina/uso terapêutico , Antioxidantes/uso terapêutico , Prognóstico , Estudos Retrospectivos , Resultado do Tratamento , Ratos WistarRESUMO
Relatar um caso de sobrecarga de ferro secundária à xerocitose, uma doença rara, em uma adolescente, diagnosticada por meio de ressonância magnética em T2*. Relatamos o caso de uma paciente sintomática com xerocitose, nível de ferritina de 350ng/mL e sobrecarga de ferro cardíaca significativa. Ela foi diagnosticada por ressonância magnética em T2* e recebeu terapia de quelação. Análise por ectacitometria confirmou o diagnóstico de xerocitose hereditária. Na sequência, a ressonância magnética em T2* demonstrou resolução completa da sobrecarga de ferro em vários órgãos e novo ecocardiograma revelou resolução completa das alterações cardíacas anteriores. A paciente permanece em terapia de quelação. Xerocitose é uma desordem genética autossômica dominante rara, caracterizada por estomatocitose desidratada. O paciente pode apresentar fadiga intensa e sobrecarga de ferro. Sugerimos o uso regular de ressonância magnética em T2* para o diagnóstico e controle da resposta à quelação de ferro em xerocitose e acreditamos que o exame pode ser útil também em outras anemias hemolíticas que necessitam de transfusões.
To report a case of iron overload secondary to xerocytosis, a rare disease in a teenager, diagnosed, by T2* magnetic resonance imaging. We report the case of a symptomatic patient with xerocytosis, a ferritin level of 350ng/mL and a significant cardiac iron overload. She was diagnosed by T2* magnetic resonance imaging and received chelation therapy Ektacytometric analysis confirmed the diagnosis of hereditary xerocytosis. Subsequent T2* magnetic resonance imaging demonstrated complete resolution of the iron overload in various organs, as a new echocardiography revealed a complete resolution of previous cardiac alterations. The patient remains in chelation therapy. Xerocytosis is a rare autosomal dominant genetic disorder characterized by dehydrated stomatocytosis. The patient may present with intense fatigue and iron overload. We suggest the regular use of T2* magnetic resonance imaging for the diagnosis and control of the response to iron chelation in xerocytosis, and we believe it can be used also in other hemolytic anemia requiring transfusions.
Assuntos
Adolescente , Feminino , Humanos , Anemia Hemolítica Congênita/diagnóstico , Hidropisia Fetal/diagnóstico , Sobrecarga de Ferro/diagnóstico , Anemia Hemolítica Congênita/complicações , Anemia Hemolítica Congênita/tratamento farmacológico , Terapia por Quelação , Desferroxamina/uso terapêutico , Hidropisia Fetal/tratamento farmacológico , Sobrecarga de Ferro/tratamento farmacológico , Sobrecarga de Ferro/etiologia , Imageamento por Ressonância Magnética , Sideróforos/uso terapêuticoRESUMO
A hemocromatose é um distúrbio autossômico recessivo ou dominante que ocorre devido ao aumento inapropriado da absorção de ferro pela mucosa gastrointestinal, resultando no armazenamento excessivo desse elemento no fígado, pâncreas, coração, articulações e gônadas. Afeta a populaçãocaucasiana, com prevalência de até um em 200 descendentes da população nórdica ou celta. O diagnóstico se faz por critérios clínicos, bioquímicos (ferritina, saturação da transferrina, etc.), genéticos epor imagem (ressonância magnética, tomografia e ultrassom).
Hemochromatosis is a disorder autosomal recessive or dominant that occurs inappropriate due to the increased absorption of iron by the gastrointestinal mucosa resulting in excessive storage of this element in the liver, pancreas, heart, joints and gonads. It affects the caucasian population with a prevalence reaching up to 1 in 200 people descendants of the population nordic or celtic. The diagnosis is made by clinical criteria, biochemical (ferritin, transferrin saturation of and so on), genetic and by image (magnetic resonance, tomography and ultrasound).
Assuntos
Humanos , Sobrecarga de Ferro/genética , Hemocromatose/genética , Ácido Ascórbico/uso terapêutico , Vitamina B 12/uso terapêutico , Fatores de Risco , Flebotomia , Desferroxamina/uso terapêutico , Fenômenos Genéticos , Dieta Rica em Proteínas , Hemocromatose/terapiaRESUMO
El hierro es el componente principal de la hemoglobina y forma también parte de la mioglobina y enzimas. Su déficit es la causa más común de anemia nutricional en el hombre. El uso de sales de hierro en pediatría es muy frecuente, ya que se indican como profilaxis y tratamiento de la anemia ferropénica.La disponibilidad en los hogares y la aparición de formulaciones saborizadas que favorecen la adhesión terapéutica, colaboran en gran medida en este tipo de intoxicación. Habitualmente, la sobredosis se considera de baja peligrosidad, por tratarse de un suplemento mineral adicionado en muchos de los alimentos infantiles. El hierro en estado libre es capaz de producir toxicidad y alterar múltiples procesos celulares al catalizar reacciones rédox con peroxidación de lípidos y formación de radicales libres. Presentamos un caso clínico de intoxicación grave, donde la intervención precoz y la administración del quelante específico permitieron una evolución favorable.
Assuntos
Humanos , Masculino , Pré-Escolar , Desferroxamina/uso terapêutico , Intoxicação/terapia , Sais de Ferro/efeitos adversos , Sulfato Ferroso/efeitos adversos , ToxicidadeRESUMO
Beta-thalassaemia major causes severe anaemia and patients with it may be transfusion-dependent for life. Regular blood transfusions cause iron-overload that leads to oxidative damage which can hasten mortality. The objective of this research was to study the oxidant-antioxidant indices in β-thalassaemia major patients at the University of Malaya Medical Centre (UMMC) who were on desferrioxaminechelation or without chelation therapy. Blood was collected from 39 Chinese patients and 20 controls. Plasma and peripheral blood mononuclear cell lysates (PBMC) were extracted and biochemical tests to evaluate oxidative stress were performed. Oxidative stress was evident in these patients as advanced oxidized protein products (AOPP) and lipid hydroperoxides were elevated, whereas glutathione peroxidase activity and the ferric reducing antioxidant power (FRAP) were reduced. The catalase activity in the patients' PBMC was elevated, possibly as a compensatory mechanism for the reduced glutathione peroxidase activity in both red blood cells and PBMC. The lower FRAP and higher AOPP levels in the non-chelated patients compared with the chelated patients were indicative of a lower oxidative stress level in the chelated patients. The ferritin levels in the chelated and non-chelated patients were high and the mean levels of liver enzyme activities in the majority of patients were elevated regardless of chelation therapy. In conclusion, this study indicates that desferrioxamine chelation therapy does not normalize ferritin level but attenuates oxidative damage and improves total antioxidant level in Malaysian Chinese β-thalassaemia major patients.
La beta-talasemia mayor causa anemia severa, y los pacientes con este padecimiento pueden hacerse dependientes de las transfusiones de sangre por el resto de sus vidas. Las transfusiones regulares de sangre dan lugar a una sobrecarga de hierro que conduce al dano oxidativo, el cual a su vez puede acelerar la mortalidad. El objetivo de esta investigación fue estudiar las tasas de oxidantesantioxidantes en pacientes de beta-talasemia mayor en el Centro Médico de la Universidad de Malaya, tanto aquellos bajo tratamiento de quelación con deferoxamina, como aquellos sin terapia de quelación alguna. Se recogieron muestras de sangre de 39 pacientes chinos y 20 controles. Se extrajeron plasma y lisados de celulas mononucleares perifericas (CMSP), y se realizaron pruebas bioquimicas para evaluar el estrés oxidativo. El estrés oxidativo era evidente en estos pacientes en forma de productos avanzados de oxidación de proteinas (PAOP), y los hidroperoxidos de lipidos eran elevados, en tanto que la actividad de glutatión peroxidasa y el poder reductor ferrico/antioxidante (FRAP) era reducida. La actividad de la catalasa en los pacientes de CMSP era elevada, posiblemente como un mecanismo compensatorio frente a la actividad de glutatión peroxidasa reducida tanto en los globulos rojos como en las CMSP. Los niveles más bajos de FRAP y los más altos de PAOP en los pacientes no quelados en comparación con los pacientes quelados, indicaban un bajo nivel de estrés oxidativo en los pacientes quelados. Los niveles de ferritina tanto en los pacientes quelados como en los no quelados, eran altos, y los niveles promedio de actividades enzimaticas del higado fueron elevados en la mayoria de los pacientes, independientemente de la terapia de quelación. En conclusión, este estudio indica que la terapia de quelación con deferoxamina no normaliza el nivel de ferritina, pero en cambio atenua el daño oxidativo, y mejora el nivel antioxidante total en los pacientes sinomalayos afectados por la betatalasemia mayor.
Assuntos
Adolescente , Criança , Feminino , Humanos , Masculino , Terapia por Quelação/métodos , Desferroxamina/uso terapêutico , Ferritinas/sangue , Sideróforos/uso terapêutico , Talassemia beta/sangue , Talassemia beta/tratamento farmacológico , Análise de Variância , Estudos de Casos e Controles , China/etnologia , Glutationa Peroxidase/sangue , Peróxidos Lipídicos/sangue , Malásia , Estresse Oxidativo/efeitos dos fármacos , Xantina Oxidase/sangue , Talassemia beta/enzimologiaRESUMO
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients and assess the ocular side-effects of iron chelating agents. Materials and Methods: In this prospective observational study, 45 multiple transfused beta-thalassemia major children between six months and 21 years of age were enrolled and assigned groups according to the treatment regimens suggested. Group A received only blood transfusions, Group B blood transfusions with subcutaneous desferrioxamine, Group C blood transfusions with desferrioxamine and oral deferriprone and Group D blood transfusions with deferriprone. Ocular status at the time of enrolment was documented. Subjects were observed quarterly for one year for changes in ocular status arising due to the disease process and due to iron chelation therapy. Children with hemoglobinopathies other than beta-thalassemia major, congenital ocular anomalies and anemia due to other causes were excluded. Results: Ocular involvement was observed in 58% of patients. Lenticular opacities were the most common ocular finding (44%), followed by decreased visual acuity (33%). An increased occurrence of ocular changes was observed with increase of serum ferritin and serum iron levels as well as with higher number of blood transfusions received. Desferrioxamine seemed to have a protective influence on retinal pigment epithelium (RPE) mottling. Occurrence of lenticular opacities and RPE degeneration correlated positively with use of desferrioxamine and deferriprone respectively. Follow-up of patients for one year did not reveal any change in ocular status. Conclusion: Regular ocular examinations can aid in preventing, delaying or ameliorating the ocular complications of thalassemia.
Assuntos
Adolescente , Transfusão de Sangue , Catarata/etiologia , Criança , Pré-Escolar , Desferroxamina/uso terapêutico , Oftalmopatias/etiologia , Oftalmopatias/fisiopatologia , Feminino , Humanos , Lactente , Quelantes de Ferro/uso terapêutico , Masculino , Piridonas/uso terapêutico , Epitélio Pigmentado da Retina/patologia , Acuidade Visual , Adulto Jovem , Talassemia beta/complicações , Talassemia beta/terapiaRESUMO
A Hemocromatose Hereditária (HH) é a desordem hereditária mais comum em caucasianos. Mais de 90% dos casos de HH resultam da simples substituição do aminoácido Cisteína pela Tirosina no gene HFE. Essa mutação causa uma doença recessiva que resulta no acúmulo tissular de ferro. O mecanismo através do qual o HFE influencia a homeostase do ferro nas células e no corpo permanece obscuro. A doença é subdiagnosticada na população em geral devido à inespecificidade de sua apresentação clínica. O prognóstico envolve a detecção precoce da doença e a terapêutica adequada utilizando a flebotomia em fase oportuna. Essa revisão descreve os conceitos atuais a respeito das manifestações clínicas, fisiopatologia, prognóstico e tratamento da Hemocromatose Hereditária relacionada ao gene HFE.
Hereditary hemochromatosis (HH) is the most common inherited disorder in caucasians. Over 90% of the cases of HH result from a single mutation of a Cys to Tyr in the HFE gene. This mutation causes a recessive disease resulting in iron acumulation in selected tissues. The mechanism by which HFE influences iron homeostasis in cells and in the body remains elusive. The disease is underdiagnosed in general population due to inespecific clinical manifestations. Prognosis is related to early diagnostic and correct treatment using pheblotomy. This review describe the current concepts concerning the clinical features, pathophisiology, prognosis and treatment of HFE-related hemochromatosis hereditary.
Assuntos
Humanos , Sobrecarga de Ferro/genética , Proteína da Hemocromatose/genética , Hemocromatose/diagnóstico , Hemocromatose/genética , Hemocromatose/terapia , Mutação/genética , Brasil , Flebotomia/instrumentação , Desferroxamina/uso terapêutico , População Branca/genéticaRESUMO
The aim of this study was to characterize a group of patients (n=8) with sickle cell disease (SCD) and ischemic stroke concerning the clinical, neurological, imaging and progressive aspects. Data were collected from records and completed with an interview of patients and their parents. In this study there were 8 patients with ages ranging from 10 to 23 years old; SCD diagnosis was given between one and two years of age with clinical features of fatigue and anemia. The stroke was ischemic in all individuals and the first cerebrovascular event occurred before 6 years of age; 3 patients had recurrence of stroke despite prophylactic blood transfusion therapy and both cerebral hemispheres were affected in 4 patients. Clinical and neurological current features observed were: acute pain crises, sialorrhea, mouth breathing, motor, and neuropsychological impairments resulting from cortical-subcortical structure lesions.
O objetivo deste estudo foi caracterizar um grupo de sujeitos (n=8) com antecedentes de anemia falciforme (AF) e acidente vascular cerebral (AVC) isquêmico, dos pontos de vista clínico, neurológico, radiológico e evolutivo, reavaliados através de exame neurológico e neuropsicológico. A partir de prontuários dos sujeitos com diagnóstico comprovado de AF e AVC, coletamos dados, complementados por entrevista com pacientes e responsáveis. Foram avaliados 8 pacientes; atualmente com idades entre 10 e 23 anos; diagnóstico da AF entre um e dois anos; quadro clínico de fraqueza e anemia. Em todos, o AVC foi isquêmico e o primeiro evento na maioria ocorreu antes dos 6 anos de idade; houve recorrência do AVC em 3, apesar da profilaxia com transfusão sanguínea; ambos os hemisférios afetados em 4; no quadro clínico e neurológico atual constatamos crises dolorosas, sialorréia, respiração oral e importante comprometimento motor e neuropsicológico, resultantes de lesões estruturais cortico-subcorticais.
Assuntos
Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Anemia Falciforme/complicações , Acidente Vascular Cerebral/etiologia , Anemia Falciforme/terapia , Transfusão de Sangue , Desferroxamina/uso terapêutico , Entrevistas como Assunto , Testes Neuropsicológicos , Sideróforos/uso terapêutico , Acidente Vascular Cerebral/terapiaRESUMO
As hemoglobinopatias mais freqüentes em nosso meio são as doenças, falciforme e talassemia, cujos portadores geralmente são dependentes de transfusão de sangue e quelação do ferro. A desferroxamine administrada sub-cutâneamente é a terapia padrão ouro, cuja administração deve ser lenta e contínua. A baixa adesão constitui a ameaça mais importante para a ocorrência de complicações, e é o maior desafio para a atuação do enfermeiro. Este trabalho tem como objetivo identificar as principais barreiras à adesão e demonstrar como o enfermeiro pode intervir, por meio de um estudo de revisão da literatura. Neste estudo foi possível observar que a maioria dos fatores que afetam a adesão à terapia quelante é de ordem prática ou psicológica. Neste contexto, considero que a maioria destas barreiras pode ser resolvida ou minimizada pela intervenção do enfermeiro capacitado.
Assuntos
Humanos , Recém-Nascido , Anemia Falciforme/enfermagem , Desferroxamina/uso terapêutico , Sobrecarga de Ferro/enfermagem , Talassemia/enfermagem , Cuidados de Enfermagem , Pacientes Desistentes do TratamentoRESUMO
A 16-yr-old male patient with hemochromatosis due to multiple packed red blood cell transfusions was referred to our emergency center for the treatment of severe aplastic anemia and dyspnea. He was diagnosed with aplastic anemia at 11-yr of age. He had received continuous transfusions because an HLA-matched marrow donor was unavailable. Following a continuous, approximately 5-yr transfusion, he was noted to develop hemochromatosis. He had a dilated cardiomyopathy and required diuretics and digitalis, multiple endocrine and liver dysfunction, generalized bleeding, and skin pigmentation. A total volume of red blood cell transfusion before deferoxamine therapy was about 96,000 mL. He received a regular iron chelation therapy (continuous intravenous infusion of deferoxamine, 50 mg/kg/day for 5 days q 3-4 weeks) for approximately seven years after the onset of multiple organ failures. His cytopenia and organ dysfunctions began to be gradually recovered since about 2002, following a 4-yr deferoxamine treatment. He showed completely normal ranges of peripheral blood cell counts, heart size, and liver function two years ago. He has not received any transfusions for the last four years. This finding suggests that a continuous deferoxamine infusion may play a role in the immune regulation in addition to iron chelation effect.
Assuntos
Adolescente , Humanos , Masculino , Anemia Aplástica/patologia , Terapia por Quelação/métodos , Desferroxamina/uso terapêutico , Transfusão de Eritrócitos , Hemocromatose/complicações , Sistema Imunitário , Ferro/uso terapêutico , Quelantes de Ferro/uso terapêutico , Radiografia Torácica/métodos , Fatores de Tempo , Resultado do TratamentoRESUMO
This study was conducted to assess the effect of age, ferritin level, hemoglobin level and chelating agents on the physical growth in thalassemic children and to determine the prevalence of dental caries in thalassemic children. Weight, standing height, sitting height and subischial leg length were measured in 65 children attending the Thalassemia day care center at a tertiary hospital in Delhi. Their mean pre transfusion hemoglobin and ferritin levels over the previous two years were calculated. Dental caries indices, DMFT and DMFS were measured and compared with age matched controls. Weight, standing height, sitting height and subischial leg length expressed as percentage for age in children >or=10 y were significantly lower than those of children < 6 y, and those 6 to 10 y. Mean hemoglobin and ferritin did not affect growth significantly. Sitting height for age in children receiving Desferrioxamine alone or Desferrioxamine with Deferiprone was significantly lower than that of children receiving Deferiprone alone or no chelating agent. Dental caries were significantly higher in thalassemics.
Assuntos
Adolescente , Adulto , Criança , Pré-Escolar , Desferroxamina/uso terapêutico , Cárie Dentária/epidemiologia , Feminino , Ferritinas/sangue , Transtornos do Crescimento/epidemiologia , Hemoglobinas/análise , Humanos , Lactente , Quelantes de Ferro/uso terapêutico , Masculino , Prevalência , Piridonas/uso terapêutico , Sideróforos/uso terapêutico , Talassemia/complicaçõesRESUMO
Cerebral malaria is the most common cause of non-traumatic encephalopathy in the world. The mainstay of therapy is either quinine or artemisinin, both of which are effective antimalarials. The clinical picture of cerebral malaria may persist or even become worse in spite of the clearance of parasites from blood. The death rate is unacceptably high even with effective antimalarials in tertiary care hospitals. The mortality increases in presence of multi organ failure (renal failure, jaundice, respiratory distress, severe anaemia, lactic acidosis, etc.). The pathogenesis of cerebral malaria is multifactorial and includes clogging, sequestration, rosette formation, release of cytokines, cerebral oedema, increased intracranial hypertension, etc. Attempts are made to use adjuvant therapy which will act through alternate mechanisms and address one or more of the pathogenetic processes. In this review, we have discussed the role of corticosteroids, pentoxifylline, desferrioxamine, mannitol and newer agents in the treatment of cerebral malaria. Though the literature on adjuvant therapy in cerebral malaria is large enough, there are a number of shortcomings in the clinical trials, many being open and non randomized or of very small sample size. Further research is of utmost importance through large multicentric, double-blind controlled trials to show the efficacy of any of these drugs.
Assuntos
Corticosteroides/uso terapêutico , Antimaláricos/uso terapêutico , Barreira Hematoencefálica/fisiopatologia , Quimioterapia Adjuvante/métodos , Desferroxamina/uso terapêutico , Humanos , Malária Cerebral/tratamento farmacológico , Manitol/uso terapêutico , Pentoxifilina/uso terapêuticoRESUMO
OBJECTIVE: Intoxication is one of the most common causes of admissions to emergency department in pediatric age group. Incidence of iron poisoning gradually increased because of wide spread use of iron containing drugs. METHOD: In this report, we present five cases of iron ingestion who were admitted to our emergency department within a year. RESULT: Whole bowel irrigation in addition to gastric lavage with an iron dose of over 50 mg/kg as well as deferoxamine treatment for patients in whom clinical and laboratory indications are present. CONCLUSION: The prompt recognition and treatment of children with acute iron poisoning is the single and the most critical point for decreasing the morbidity and mortality associated with iron containing products.
Assuntos
Pré-Escolar , Desferroxamina/uso terapêutico , Feminino , Lavagem Gástrica , Humanos , Lactente , Ferro/intoxicação , Quelantes de Ferro/uso terapêutico , Masculino , Intoxicação/terapiaRESUMO
The effects on linear growth and development among thalassemic patients under different treatment regimens were compared. Twelve homozygous beta-thalassemia (homozygous beta-thal) and 36 beta-thalassemia/Hb E (beta-thal/Hb E) were studied longitudinally between 1977 and 1998. Eighteen cases (10 homozygous beta-thal and 8 beta-thal/Hb E) received hypertransfusion with iron chelation by desferrioxamine. Another 30 cases (2 homozygous beta-thal and 28 beta-thal/Hb E) were given a low transfusion (depending on their clinical requirement). Their heights were measured serially and are presented as a standard deviation score (SDS). There was no significant difference in initial basic hematological data and ferritin levels between either group. However, the hypertransfused group, seemed to be clinically more severely affected than the other group as evidenced by early age at initial transfusion, the early onset of anemia and diagnosis and also their large acquired iron load after a period of transfusion. The average height SDS of the hypertransfused patients was within the 50th percentile +/- 1 SD during the first decade of life in both sexes and both genotypes. Whereas, in patients who were transfused infrequently, the SDS was always below the -1 SD and decreased gradually. In severe beta-thal/Hb E cases, their growth SDS showed no difference from those with homozygous beta-thal. Normal linear growth in those with homozygous beta thal and severe beta-thal/Hb E was only seen in the group that underwent hypertransfusion and this regimen contributed to normal growth during the first ten years of life. However, adequate iron chelation and hormonal treatment in these patients were also required in order to achieve normal adult height.